Crizotinib in ALK+ inflammatory myofibroblastic tumors-Current experience and future perspectives.
Till-Martin TheilenJan SoerensenKonrad BochennekMartina BeckerDirk SchwabeUdo RolleThomas KlingebielThomas LehrnbecherPublished in: Pediatric blood & cancer (2017)
Inflammatory myofibroblastic tumor (IMT) and its subtype epithelioid inflammatory myofibroblastic sarcoma (EIMS) are rare soft-tissue tumors. As about 50% of IMT and 100% of EIMS contain activating rearrangements of the anaplastic lymphoma kinase (ALK) gene, targeted kinase inhibition of ALK by compounds such as crizotinib is a potential treatment option. We performed a literature review and analyzed a total of 30 patients with IMT/EIMS treated with crizotinib. A total of 12 patients achieved complete or partial remission. As preliminary data are promising, a prospective study evaluating crizotinib treatment in patients with unresectable/multifocal ALK+ IMT/EIMS is warranted.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- end stage renal disease
- oxidative stress
- newly diagnosed
- chronic kidney disease
- soft tissue
- tyrosine kinase
- ejection fraction
- signaling pathway
- gene expression
- peritoneal dialysis
- squamous cell carcinoma
- genome wide
- systemic lupus erythematosus
- machine learning
- drug delivery
- disease activity
- rectal cancer
- genome wide identification